熱門資訊> 正文
展望Therapeutics获得FDA审查接受对AMD的湿治疗
2025-04-08 22:42
- Outlook Therapeutics (NASDAQ:OTLK) said on Tuesday that the U.S. FDA has accepted to review ONS-5010, an ophthalmic formulation of bevacizumab, for the treatment of wet age-related macular degeneration, a common cause of blindness among the elderly.
- Stock is up 9% in morning trade.
- The agency has acknowledged receipt of the resubmission of the Biologics License Application for ONS-5010, after the company reported in January that ONS-5010 demonstrated non-inferiority to ranibizumab, sold by Roche's (OTCQX:RHHBY) Genentech unit, at week 12 in a study.
- FDA set a Prescription Drug User Fee Act goal date of August 27, 2025.
- OTLK said that ONS-5010, if approved, will be branded as Lytenava in the United States for the treatment of wet AMD and is expected to receive 12 years of regulatory exclusivity.
- ONS-5010 has already received market authorization in the European Union and the United Kingdom.
More on Outlook Therapeutics
- Outlook falls 10% on ONS-5010 update, warrant inducements
- Seeking Alpha’s Quant Rating on Outlook Therapeutics
- Historical earnings data for Outlook Therapeutics
- Financial information for Outlook Therapeutics
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。